The three key themes summarised by the company for the last 12+...

The three key themes summarised by the company for the last 12+ months

1. The data from all three Phase 2 trials will be central to demonstrating to potential pharmaceutical partners and regulatory authorities the safety and efficacy of BIT225 in patients with currently unmet medical needs.

2. As with all its programs, the Company is dedicated to generating high value data to de-risk the portfolio ahead of licensing to a major pharmaceutical company for late-stage development, marketing and sales.

3. We appreciate the ongoing support and patience of shareholders while we work to achieve the long-awaitedcommercial outcomes.

So current state of play – We now have three Phase 2 data available. Great! No more waiting on data.

Now we have all central data (good, bad or indifferent) - Question is what is happening now?

Are we still having conversations with pharma to achieve long-awaited commercial outcomes??